HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients with advanced NEN and other solid tumors
Solid Tumors|Neuroendocrine Tumors|CRC
DRUG: HBM4003|DRUG: Toripalimab|DRUG: Tislelizumab
Part 1: DLT, Number of subjects with DLT in each dose cohort within 1 cycle (21 days) after the first drug administration, approximate 21 days|Part 1: MTD, The maximum tolerated dose (MTD) of HBM4003 combined with Toripalimab, approximate 21 days|Part 1: RP2D, The recommended phase 2 dose (RP2D) of HBM4003 combined with Toripalimab, approximate 21 days|Part 2: ORR, Proportion of subjects with complete response (CR) and partial response (PR), maximum 2 years
Subjects will be treated with HBM4003 in combination with Toripalimab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first.

This trial consists of:

* A screening period: 28 days
* A treatment period: no longer than 2 years (Part 1 dose escalation study or Part 2 dose expansion)
* A post-treatment follow-up period, including 28 days and 84 days after the last dose of study drug;
* Survival follow-up.